serplulimab
Hetronifly (serplulimab) is a PD-1 checkpoint inhibitor from Accord Healthcare used in the European Union with chemotherapy as first-line treatment for extensive-stage small cell lung cancer, non-squamous non-small cell lung cancer without EGFR, ALK, or ROS1 mutations, and PD-L1-positive esophageal squamous cell carcinoma.
This page is based on the EMA medicine record for serplulimab, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Lung and esophageal tumours can raise a molecular white flag that presses the PD-1 brake on attacking T cells, so the immune patrol stands down. Serplulimab covers the brake. The flag no longer works, the T cells stay switched on, and they attack the cancer alongside chemotherapy.
In simple terms
Serplulimab is a monoclonal antibody given by intravenous infusion that targets PD-1, an off-switch expressed on T cells. Many cancers display the ligands PD-L1 and PD-L2, which bind PD-1 and suppress the immune response against them. Serplulimab binds PD-1 and blocks that signalling, restoring T-cell activation and T-cell-mediated attack on tumour cells. It is combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer, selected non-small cell lung cancer, and PD-L1-positive esophageal squamous cell carcinoma.
In depth
Serplulimab is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279). Upon administration it targets, binds to, and inhibits PD-1 and its downstream signalling pathways, which may restore immune function through the activation of T cells and T-cell-mediated immune responses against tumour cells. PD-1 is a transmembrane protein in the immunoglobulin superfamily expressed on T cells that functions as an immune checkpoint negatively regulating T-cell activation and effector function when engaged by its ligands PD-L1 or PD-L2, and it plays an important role in tumour evasion from host immunity.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How serplulimab, a humanized anti-PD-1 antibody, frees T cells in lung and esophageal cancer
- Serplulimab is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279).
- Many cancers display the ligands PD-L1 and PD-L2, which bind PD-1 and suppress the immune response against them.
- Serplulimab binds PD-1 and blocks that signalling, restoring T-cell activation and T-cell-mediated attack on tumour cells.
- It is combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer, selected non-small cell lung cancer, and PD-L1-positive esophageal squamous cell carcinoma.
Target: Programmed death-1 (PD-1) receptor
An immune checkpoint on T cells; when its ligands PD-L1 and PD-L2 activate it, T-cell activation and effector function are suppressed, which tumours exploit to escape immune attack.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- In combination with carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer
- In combination with carboplatin and pemetrexed, for the first-line treatment of adults with non-squamous non-small cell lung cancer with no EGFR, ALK, or ROS1 positive mutations who have locally advanced disease that is not amenable to surgery or radiotherapy, or metastatic disease
- In combination with fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of adults with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS of 5 or more
Official sources
The statements on this page trace back to these records.
- Hetronifly (serplulimab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- National Cancer Institute: serplulimab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.